Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib

JAMA Oncology Author Interviews: Covering research, science, & clinical practice in oncology that improves the care of patients with cancer by American Medical Association

Interview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Cont...View more